<DOC>
	<DOC>NCT01152216</DOC>
	<brief_summary>An open-label extension study of the CONCERT (DIM18) protocol evaluating the safety of dimebon (latrepirdine) in subjects with With Mild-to-Moderate Alzheimer's Disease on Donepezil.</brief_summary>
	<brief_title>An Extension of the CONCERT Protocol (DIM18)</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Successful completion of the 12 month DIM18 CONCERT study Mildtomoderate Alzheimer's disease Probable AD, Diagnostic and Statistical Manual of Mental DisordersIVText Revised (DSMIVTR) MiniMental State Exam (MMSE) score between 12 and 24, inclusive Stable on donepezil for at least 6 months Other causes of dementia Major structural brain disease Unstable medical condition or significant hepatic or renal disease</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>